The Division of Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital and The Ohio State University, Columbus, OH, 43205, USA.
The Ohio State University College of Medicine, Columbus, OH, 43210, USA.
Childs Nerv Syst. 2022 Feb;38(2):465-472. doi: 10.1007/s00381-021-05197-6. Epub 2021 May 4.
Wnt-activated medulloblastoma (MB) confers an excellent prognosis. However, specific treatment strategies for patients with relapsed Wnt-MB are unknown. We report two patients with recurrent beta-catenin nucleopositive Wnt-MB successfully treated by incorporating marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue (HDCx/AuHPCR). We also present a review of the literature for previously reported cases of relapsed Wnt-MB. We propose that patients with recurrent Wnt-MB may be treated using a multi-disciplinary approach that includes HDCx/AuHPCR with or without re-irradiation.
Wnt 激活型髓母细胞瘤（MB）预后良好。然而，对于复发的 Wnt-MB 患者，尚无明确的特定治疗策略。我们报告了两例复发的β-连环蛋白阳性 Wnt-MB 患者，他们成功地接受了骨髓清除化疗和自体造血祖细胞挽救（HDCx/AuHPCR）治疗。我们还对先前报道的复发 Wnt-MB 病例进行了文献复习。我们提出，对于复发的 Wnt-MB 患者，可以采用多学科治疗方法，包括 HDCx/AuHPCR 联合或不联合再放疗。
